Last $0.31 USD
Change Today 0.00 / 0.00%
Volume 0.0
ACCP On Other Exchanges
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

access pharmaceuticals inc (ACCP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/14 - $0.60
52 Week Low
12/24/13 - $0.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

access pharmaceuticals inc (ACCP) Related Businessweek News

No Related Businessweek News Found

access pharmaceuticals inc (ACCP) Details

Access Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. Its marketed product includes MuGard for the management of oral mucositis. The company’s products under development comprise ProctiGard for the management of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region; LexaGard for the treatment of conditions of the upper gastrointestinal tract, including Barrett’s esophagus and esophagitis; CobOral, a preclinical nanopolymer oral drug delivery technology based on the natural vitamin B12 oral uptake mechanism; and CobaCyte, a preclinical nanopolymer that constructs to deliver anti-cancer drug to tumors protecting normal tissues. Access Pharmaceuticals, Inc. is based in Dallas, Texas.

6 Employees
Last Reported Date: 07/2/14

access pharmaceuticals inc (ACCP) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $503.0K
Total Annual Compensation: $129.0K
Compensation as of Fiscal Year 2013.

access pharmaceuticals inc (ACCP) Key Developments

Access Pharmaceuticals Announces European License Agreement with Norgine

Access Pharmaceuticals announced that it had entered into an exclusive license agreement with Norgine B.V. for the commercialization of MuGard in Europe. Under the terms of the license agreement, Access will receive up to $10 million in milestone payments and an escalating double digit royalty on the net sales of the oral mucositis product, MuGard, in the licensed territories. Norgine will develop, manufacture, and commercialize MuGard in the European Union, Switzerland, Norway, Iceland and Lichtenstein. Norgine anticipates launching MuGard in 2015.

Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance for ProctiGard(TM)

Access Pharmaceuticals Inc. announced that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard(TM), its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of ProctiGard(TM) is a direct response to dialogue with the oncology community that is looking for better, more effective treatment options for rectal mucositis and radiation proctitis, a debilitating oncology side effect. Access believes that ProctiGard is a treatment option that addresses a significant unmet medical need. Access currently holds global commercialization rights for ProctiGard.

Access Pharmaceuticals Inc. Receives Hong Kong Patent For MuGard

Access Pharmaceuticals Inc. has received notification from the Hong Kong Patent Office that a patent for MuGard has been granted. The patent protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. Access recently announced that one of the oldest peer-reviewed journals in oncology, the American Cancer Society's journal publication, Cancer, featured MuGard as the cover article of its May 2014 edition.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACCP:US $0.31 USD 0.00

ACCP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $16.77 USD -0.06
DARA Biosciences Inc $1.16 USD -0.01
Flamel Technologies SA $14.06 USD -0.0559
Merrion Pharmaceuticals Plc €0.40 EUR 0.00
XenoPort Inc $5.24 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation ACCP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCESS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at